Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional Results available

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

NCT01245673
View directory record Official record
Conditions
Myeloma
Interventions
Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
Biological · Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients

NCT01554956
View directory record Official record
Conditions
Ligneous Conjunctivitis
Interventions
Human Plasminogen
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

NCT00317694
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Fermagate, Placebo
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Pine Bluff, Arkansas • Stuttgart, Arkansas • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2009 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 3 Interventional

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

NCT00685256
View directory record Official record
Conditions
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions
counseling intervention, educational intervention, survey administration, psychosocial assessment and care, supportive care
Other · Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
8 Years to 120 Years · Female only
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Launch II: A Pilot Randomized Control Trial of a Clinic and Clinic Plus Home Intervention for Preschool Obesity

NCT01419951
View directory record Official record
Conditions
Obesity
Interventions
Clinic + Home Behavioral Intervention, Pediatrician Counseling, Clinic Only Behavioral Intervention
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 5 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

NCT03118466
View directory record Official record
Conditions
AML
Interventions
Etoposide, Cytarabine, Lenalidomide, Mitoxantrone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 29, 2026, 9:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD0754 in Participants With Metastatic Prostate Cancer

NCT06267729
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
AZD0754, AZD2287
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 29, 2026, 9:59 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

NCT00642902
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Phoenix, Arizona • Atlanta, Georgia • Northbrook, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 29, 2026, 9:59 PM EDT
Terminated Phase 2 Interventional Results available

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

NCT01953354
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Trichuris suis ova (TSO), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Palo Alto, California • New Haven, Connecticut • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00110994
View directory record Official record
Conditions
Cancer, Melanoma
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo, Dacarbazine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
14
States / cities
Tucson, Arizona • Aurora, Colorado • Lakeland, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 2 Interventional

Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

NCT06384157
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
INDV-2000, Placebo
Drug · Other
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
35
States / cities
Hamilton, Alabama • Phoenix, Arizona • Oceanside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Translation of District Sun Safe Policies to Schools

NCT03243929
View directory record Official record
Conditions
Sun Safety, Sun Safe Schools, Prevention of Skin Cancer
Interventions
Translation of District Sun Safe Policies to Schools, Attention Control
Behavioral
Lead sponsor
Claremont Graduate University
Other
Eligibility
Not listed
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Claremont, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 29, 2026, 9:59 PM EDT
Terminated Phase 3 Interventional

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

NCT04457245
View directory record Official record
Conditions
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography, Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 29, 2026, 9:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Study of Food Aversion in Patients With Anorexia Nervosa

NCT03100656
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
A breakfast sandwich
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 29, 2026, 9:59 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06736041
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
66
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

NCT02140151
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Southern California Desert Retina Consultants, MC
Other
Eligibility
50 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 29, 2026, 9:59 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

NCT00035529
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Placebo, BMS 188667 (Abatacept)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Worcester, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 2 Interventional

Phase II BGG492 Capsule Extension for Partial Epilepsy

NCT01338805
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
BGG492
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 66 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tallahassee, Florida • Hamilton, New Jersey • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

NCT02510794
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 29, 2026, 9:59 PM EDT
Terminated Phase 3 Interventional

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

NCT00306137
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Glioma Supra Marginal Incision Trial

NCT04737577
View directory record Official record
Conditions
High Grade Glioma
Interventions
Supramarginal resection, Conventional (i.e. GTR) resection
Procedure
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 29, 2026, 9:59 PM EDT
Not listed Not applicable Interventional

BFR DISTRAD NON OP: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture

NCT03056950
View directory record Official record
Conditions
Distal Radius Fracture, Rehabilitation
Interventions
DELFI PTS ii portable tourniquet
Device
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 1 Interventional

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

NCT01912820
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
green tea extract, quercetin, placebo, therapeutic conventional surgery, laboratory biomarker analysis
Dietary Supplement · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 29, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer

NCT01620593
View directory record Official record
Conditions
Prostate Cancer
Interventions
Placebo, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 29, 2026, 9:59 PM EDT